The Study Of The Impact Of XFK Oral Liquid On The Cardiac Function And High-energy Phosphate Metabolism Of Heart Failurerats

Background:Chronic heart failure is a heart ariety of organic or functional disease syndrome caused by ventricular ejection compromised. With the increase in incidence of the acceleration of the aging of the population,as well as hypertension,coronary heart disease and other cardiovascular disease,the prevalence of heart failure is increasing everyyear. Heart failure is the final outcome of various heart diseases. With a deeper understanding of the pathogenesis of CHF,theresearch of therapy drugs has made great development, ACEI and other drugs are also widely used in clinical. Nevertheless because of thehigh mortality caused by CHF,it is also a hugedisease threat to human health. The use of cardiac resynchronization therapy even heart transplantation means they need to spend a lot of medical resources.SoThere is an urgent need tofind new and more effective means of treatment in CHF. Myocardial cell energy metabolism lead to heart failure and the development of an important mechanism. Study also found that the potential clinical applications for this area. In this experiment, heart failure, myocardial energy metabolism as a starting point.Objctive:By study XinFuKang oral affect metabolism and heart failure cardiac function in rats with heart failure high-energy phosphate compounds,to explore the mechanism of action of XFKin the oral treatment of CHF energy metabolism.And to explore way to use the31P-NMR technology in the field of energy metabolism in CHF of the Traditional Chinese Medicine.Method:Heart failurerats are created by ligating the left anterior descending artery.And the rats are randomly divided into Sham group,Model group,Catopril group,XFK High-dose group and XFK Low-dose group. The experiment lasted four weeks,and then take the myocardial tissue of CHF rats used to detecte the myocardial high-energy phosphate31P-NMR.Detect changes in cardiac function in rats by Echocardiography. Result:1.The impact of XFK oral in cardiac function in rats with heart failure after myocardial infarction.1.1The impact of XFK oral in LVIDd.LVIDs in rats with heart failure after myocardial infarction.Compared with Sham group:After surgery, the LVIDd,LVIDs of Model group,Catopril group,XFK High-dose group and XFK Low-dosegroup are Increased, Statistically significant(P<0.01).After4w of drug intervention, the LVIDd,LVIDs of Model groupis Increased and Statistically significant(P<0.01).Compared with Model group:After4w of drug intervention, the LVIDd,LVIDsof Catopril group,XFK High-dose groupare Reduced, Statistically significant(P<0.01). The LVIDd ofXFK Low-dosegroupis Reduced, Statistically significant(P<0.01). The LVIDs ofXFK Low-dosegroupis Reduced, Statistically significant(P<0.05).1.2The impact of XFK oral in EF,FS,CO in rats with heart failure after myocardial infarction.Compared with Sham group:After surgery, the EF,FS,CO of Model group,Catopril group,XFK High-dose group and XFK Low-dosegroup are Reduced, Statistically significant(P<0.01).After4w of drug intervention, the EF,FS,CO of Model groupis Reducedand Statistically significant(P<0.01).Compared with Model group:After4w of drug intervention, the EF,FS,CO of Catopril group are Increased, Statistically significant(P<0.01). The EF,FS,CO of XFK High-dose group andXFK Low-dosegroupare Increased, Statistically significant(P<0.05). The CO ofXFK High-dose group and XFK Low-dosegroupare Increased, Statistically significant(P<0.01).2. The impact of XFK oral in High-energy phosphate metabolism in rats with heart failure after myocardial infarction.Compared with Sham group:After4w of drug intervention, the ADP/ATP,Pi/ATP of Model group are Increased, Statistically significant(P<0.01). the PCr/ATP of Model group is Reduced, Statistically significant(P<0.01). Compared with Model group:After4w of drug intervention, the ADP/ATP, Pi/ATP of Catopril group are Reduced, Statistically significant(P<0.01). The PCr/ATP of Model group is Increased, Statistically significant(P<0.01). The ADP/ATP,Pi/ATP of XFK High-dose group are Reduced, Statistically significant(P<0.01). The PCr/ATP of XFK High-dose group is Increased, Statistically significant(P<0.05). The ADP/ATP of XFK Low-dose group is Reduced, Statistically significant(P<0.05), The Pi/ATP of XFK Low-dose group is Reduced, Statistically significant(P<0.01),The PCr/ATP of XFKLow-dose group is Increased, Statistically significant(P<0.05).Conclusion:1.XFK could reduce the LVIDd and LVIDs of rats with heart failure after myocardial infarction, Reverse ventricular remodeling of CHF rats.2. XFK could Improve the EF and FS of rats with heart failure after myocardial infarction, Improve the ability of the heart’s contraction of CHF rats.3. XFK could Improve the CO of rats with heart failure after myocardial infarction, Improve the ability of the heart’s ejection of CHF rats.4. XFK could Improve the PCr/ATP of rats with heart failure after myocardial infarction, Improve the efficiency of myocardial creatine phosphate shuttle of CHF rats.5. XFK could reduce the ADP/ATP of rats with heart failure after myocardial infarction, Improve the The cardiac ADP and ATP conversion efficiency of CHF rats.6. XFK could reduce the Pi/ATP of rats with heart failure after myocardial infarction, Improve the Myocardial ATP synthesis efficiency of CHF rats.